ΔF508 is the most prevalent mutation detected in patients with cystic fibrosis (CF), and it causes a loss of F508 within CFTR’s first nucleotide binding domain (NBD1). Researchers from Sionna ...
Cystic fibrosis (CF) remains an exemplar of how detailed molecular understanding can fuel transformative advances in treatment. Research in this field spans elucidating the genetic and cellular ...
EMERYVILLE, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (FDMT) (Nasdaq: FDMT, 4DMT, or the Company), a leading late-stage biotechnology company advancing durable and ...
(RTTNews) - 4D Molecular Therapeutics Inc. (FDMT) on Wednesday reported positive interim results from its Phase 1 AEROW study evaluating 4D-710, the company's gene therapy candidate for the treatment ...
A new study from The Hospital for Sick Children (SickKids) reveals the process underlying protein organization on cell membranes, a finding which could pave the way for innovative cystic fibrosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results